Ligand Pharmaceuticals Incorporated Investigation
The law firm of Kirby McInerney LLP is investigating potential claims against Ligand Pharmaceuticals Incorporated ("Ligand" or the "Company") (NASDAQ: LGND). This investigation concerns whether Ligand has violated federal securities laws and/or engaged in other unlawful business practices.
On January 16, 2019, Citron Research published a report entitled "Pipeline Ligand Pipe Dream," detailing sources of Ligand's future revenues by drug candidate, showing how roughly 60% of the Company's milestone payments stem from just two companies. The report alleges that some of Ligand's partners have corporate addresses that are really a home or UPS box, or do not occupy their supposed address. Following this news, the price of Ligand shares fell $21.72, or approximately 16.5%, to close at $110.05 on January 16, 2019.
If you acquired Ligand securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney LLP at 212-371-6600, by email at email@example.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.